Multiple system atrophy and myoclonus
A morphologic marker in the spinal cord?
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published August 12, 2019.
Author Disclosures
- Lorraine V. Kalia, MD, PhD, FRCPC and
- Kurt A. Jellinger, MD, PhD
- Lorraine V. Kalia, MD, PhD, FRCPC and
(1) NINDS Parkinson's Disease Biospecimen Review Access Committee (PD BRAC)
NONE
(1) Allergen Inc., funding for travel to attend conference (2) British Pharmacological Society, funding for travel to speak at conference (3) Canadian Institutes of Health Research, funding for travel to speak at conference (4) Canadian Neurological Sciences Federation, funding for travel to speak at conference (5) International Association of Parkinsonism and Related Disorders, funding for travel to speak at conference (6) Michael J. Fox Foundation for Parkinson?s Research, funding for travel to speak at conference (7) Shire, honorarium to speak at conference (8) University of Alberta, funding to speak at conference (9) University of California Irvine, honorarium to speak at conference
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Alion Pharmaceuticals Inc. (2) ApoPharma Inc.
(1) Canadian Institutes of Health Research, Principal Investigator, 2015-2023 (2) Ontario Brain Institute, Principal Investigator, 2018- 2020 (3) Natural Sciences and Engineering Research Council of Canada, Principal Investigator, 2015-2021
NONE
(1) J. P. Bickell Foundation (2) Michael J. Fox Foundation for Parkinson?s Research (3) Parkinson Canada (4) Toronto General & Western Hospital Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Kurt A. Jellinger, MD, PhD
NONE
NONE
NONE
(1)Acta Neuropathol, executive editor, 1978-2004 (2)Acta Neuropathol, senior editor since 2005 (3)Neuropsychiatrie, editor (4)Clin Neuropathol, editor, 1982 (5)Acta Neurochir, advisory board (6)Neuropaediatrics, member of editorial board (7)Clinical Neuropathology, member of editorial board (8)Acta Neurochir (Wien), member of editorial board (9)Neurodegenerative Disorders, member of editorial board (10)Schweiz Arch Neurol Psychiatr, member of editorial board (11)J Neurol Sciences, member of editorial board (12)Neurodegeneration, member of editorial board (13)Brain Pathology, member of editorial board (14)J Neural Transm, member of editorial board (15)Parkinsonism Related Disorders, member of editorial board (16)Brain Tumor Pathology, member of editorial board (17)Exp Neurology, member of editorial board (18)J Alzheimer Disease, member of editorial board (19)Acta Neurol Scand, member of editorial board, 2005-2010 (20)J Molec Cell Pathol, member of editorial board (21)Medical Science Monitor, member of editorial board (22)Histology and Histopathology, member of editorial board (23)J Clin Neurol, member of editorial board (24)Neural Regen Res, member of editorial board (25)Int J Molec Sci, member of editorial board (26)Dement Geriatr Cogn Disord, member of editorial board, since 2009 (27)Section Editor in Chief Int J Molec Sciences, member of editorial board (28)Int. J Alzheimer's Dis, member of editorial board (29)J Pediatr Biochem, member of editorial board (30)Frontiers in Biosciences, member of editorial board, since 2009 (31)In J Clin Exp Med, member of editorial board, since 2010 (32)Neurol Regen Res, member of editorial board, since 2009 (33)Am J Neuroprotec Neuroregen, member of editorial board, since 2010 (34)J Molec Biomarkers, member of editorial board, since 2010 (35)Frontiers in Biosciences, member of editorial board, since 2010 (36)J Biolog Med, member of editorial board, since 2010 (37)Challenges, member of editorial board, since 2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Society for Support of Research in Experimental Neurology, Vienna, Austria
NONE
NONE
NONE
NONE
NONE
NONE
- From Krembil Research Institute (L.V.K.) and Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine (L.V.K.), Toronto Western Hospital, University Health Network; Division of Neurology, Department of Medicine (L.V.K.), and Tanz Centre for Research in Neurodegenerative Diseases (L.V.K.), University of Toronto, Canada; and Institute of Clinical Neurobiology (K.A.J.), Vienna, Austria.
- Correspondence
Dr. Kalia lorraine.kalia{at}utoronto.ca
Article usage
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.